EA037366B1 - Способ получения ингибитора parp, кристаллические формы и их применения - Google Patents

Способ получения ингибитора parp, кристаллические формы и их применения Download PDF

Info

Publication number
EA037366B1
EA037366B1 EA201890547A EA201890547A EA037366B1 EA 037366 B1 EA037366 B1 EA 037366B1 EA 201890547 A EA201890547 A EA 201890547A EA 201890547 A EA201890547 A EA 201890547A EA 037366 B1 EA037366 B1 EA 037366B1
Authority
EA
Eurasian Patent Office
Prior art keywords
crystalline form
compound
group
degrees
ray powder
Prior art date
Application number
EA201890547A
Other languages
English (en)
Russian (ru)
Other versions
EA201890547A1 (ru
Inventor
Хэсянь Ван
Чаню Чжоу
Бо Рэн
Сяньчжао Куан
Original Assignee
Бейджин, Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58099633&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA037366(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бейджин, Лтд. filed Critical Бейджин, Лтд.
Publication of EA201890547A1 publication Critical patent/EA201890547A1/ru
Publication of EA037366B1 publication Critical patent/EA037366B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
EA201890547A 2015-08-25 2016-08-22 Способ получения ингибитора parp, кристаллические формы и их применения EA037366B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2015088003 2015-08-25
PCT/CN2016/096200 WO2017032289A1 (en) 2015-08-25 2016-08-22 Process for preparing parp inhibitor, crystalline forms, and uses thereof

Publications (2)

Publication Number Publication Date
EA201890547A1 EA201890547A1 (ru) 2018-07-31
EA037366B1 true EA037366B1 (ru) 2021-03-18

Family

ID=58099633

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890547A EA037366B1 (ru) 2015-08-25 2016-08-22 Способ получения ингибитора parp, кристаллические формы и их применения

Country Status (15)

Country Link
US (1) US10457680B2 (OSRAM)
EP (1) EP3341375B1 (OSRAM)
JP (1) JP6940039B2 (OSRAM)
KR (1) KR20180041748A (OSRAM)
CN (2) CN112521390A (OSRAM)
AU (1) AU2016312011B2 (OSRAM)
BR (1) BR112018003634B1 (OSRAM)
CA (1) CA2994895A1 (OSRAM)
EA (1) EA037366B1 (OSRAM)
IL (2) IL296835A (OSRAM)
MX (1) MX385450B (OSRAM)
NZ (1) NZ739876A (OSRAM)
TW (1) TWI736550B (OSRAM)
WO (1) WO2017032289A1 (OSRAM)
ZA (1) ZA201800765B (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02855B (me) 2011-12-31 2018-04-20 Beigene Ltd KONDENZOVANI TETRA ILl PENTA-CIKLIČNI DIHIDRODIAZEPINOKARBAZOLONI KAO PARP INHIBITORI
JP6940039B2 (ja) 2015-08-25 2021-09-22 ベイジーン リミテッド Ｐａｒｐ阻害剤の製造方法、結晶型、及びその使用
US11202782B2 (en) 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
CN110392687B (zh) * 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
US12121518B2 (en) 2017-03-09 2024-10-22 The Board Of Supervisors Of Louisiana State Universi And Agricultural And Mechanical College PARP-1 and methods of use thereof
WO2018165615A1 (en) * 2017-03-09 2018-09-13 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Parp-1 and methods of use thereof
US20200155567A1 (en) * 2017-07-17 2020-05-21 Beigene, Ltd. Treatment of cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapy
KR20210013554A (ko) * 2018-05-18 2021-02-04 노파르티스 아게 Tlr7/tlr8 억제제의 결정질 형태
US20210205323A1 (en) * 2018-06-01 2021-07-08 Beigene, Ltd. Maintenance therapy of a parp inhibitor in treating gastric cancer
USD926356S1 (en) * 2019-03-14 2021-07-27 Tuanfang Liu Battery for electronic cigarette
CN113004279B (zh) * 2019-05-10 2023-01-06 百济神州(苏州)生物科技有限公司 一种控制含parp抑制剂倍半水合物产物的含水量的方法
CN111171002B (zh) * 2019-05-16 2021-04-06 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的制备方法
CN111171001B (zh) * 2019-05-16 2022-04-29 百济神州(苏州)生物科技有限公司 一种parp抑制剂中间体的结晶方法
US20220233550A1 (en) 2019-05-31 2022-07-28 Beigene, Ltd. Parp inhibitor pellet preparation and preparation process therefor
CN112007011B (zh) * 2019-05-31 2024-07-23 百济神州(苏州)生物科技有限公司 一种parp抑制剂微丸胶囊及其制备工艺
WO2021046014A1 (en) 2019-09-03 2021-03-11 Teva Czech Industries S.R.O Solid state forms of pamiparib and process for preparation thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
WO2025034702A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Rmc-6291 for use in the treatment of ras protein-related disease or disorder
TW202530228A (zh) 2023-10-12 2025-08-01 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025217307A1 (en) 2024-04-09 2025-10-16 Revolution Medicines, Inc. Methods for predicting response to a ras(on) inhibitor and combination therapies
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044183A2 (en) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
WO2004063198A1 (en) * 2003-01-09 2004-07-29 Pfizer Inc. Diazepinoindole derivatives as kinase inhibitors
WO2013097225A1 (en) * 2011-12-31 2013-07-04 Beigene, Ltd. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50031B (sr) 1999-01-11 2008-11-28 Agouron Pharmaceuticals Inc., Triciklični inhibitori poli(adp-riboza)polimeraza
PT2767537T (pt) 2008-08-06 2017-07-17 Medivation Technologies Inc Inibidores de di-hidropiridoftalazinona de poli(adp-ribose)polimerase (parp)
RS63571B9 (sr) 2013-09-13 2023-02-28 Beigene Switzerland Gmbh Anti-pd1 antitela i njihova primena kao terapeutska i dijagnostička sredstva
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
US9637488B2 (en) 2015-01-29 2017-05-02 Fuqiang Ruan Heterocyclic compounds as inhibitors of class I PI3KS
JP6940039B2 (ja) 2015-08-25 2021-09-22 ベイジーン リミテッド Ｐａｒｐ阻害剤の製造方法、結晶型、及びその使用
US11202782B2 (en) * 2016-09-27 2021-12-21 Beigene, Ltd. Treatment cancers using a combination comprising PARP inhibitors
CN110392687B (zh) * 2017-02-28 2022-08-02 百济神州(苏州)生物科技有限公司 稠合的四环或五环二氢二氮杂䓬并咔唑酮的盐的结晶形式及其用途
US20200155567A1 (en) * 2017-07-17 2020-05-21 Beigene, Ltd. Treatment of cancers using a combination comprising parp inhibitors, temozolomide and/or radiation therapy
CN113004279B (zh) * 2019-05-10 2023-01-06 百济神州(苏州)生物科技有限公司 一种控制含parp抑制剂倍半水合物产物的含水量的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002044183A2 (en) * 2000-12-01 2002-06-06 Guilford Pharmaceuticals Inc. Benzoazepine and benzodiazepine derivatives and their use as parp inhibitors
WO2004063198A1 (en) * 2003-01-09 2004-07-29 Pfizer Inc. Diazepinoindole derivatives as kinase inhibitors
WO2013097225A1 (en) * 2011-12-31 2013-07-04 Beigene, Ltd. Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as parp inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"RN: 1858211-28-5" STN Registry, 02 February 2016 (2016-02-02) *

Also Published As

Publication number Publication date
CN112521390A (zh) 2021-03-19
US10457680B2 (en) 2019-10-29
MX385450B (es) 2025-03-18
BR112018003634A8 (pt) 2023-01-17
JP6940039B2 (ja) 2021-09-22
NZ739876A (en) 2022-09-30
CN107922425B (zh) 2021-06-01
AU2016312011B2 (en) 2021-02-04
US20190177325A1 (en) 2019-06-13
IL296835A (en) 2022-11-01
TWI736550B (zh) 2021-08-21
BR112018003634B1 (pt) 2023-11-21
KR20180041748A (ko) 2018-04-24
WO2017032289A1 (en) 2017-03-02
CN107922425A (zh) 2018-04-17
IL257442B (en) 2022-11-01
BR112018003634A2 (en) 2018-11-21
MX2018002322A (es) 2018-04-11
TW201718586A (zh) 2017-06-01
EP3341375B1 (en) 2022-04-13
ZA201800765B (en) 2019-10-30
EP3341375A4 (en) 2019-01-16
IL257442A (en) 2018-04-30
JP2018528199A (ja) 2018-09-27
EP3341375A1 (en) 2018-07-04
IL257442B2 (en) 2023-03-01
EA201890547A1 (ru) 2018-07-31
CA2994895A1 (en) 2017-03-02
AU2016312011A1 (en) 2018-03-08

Similar Documents

Publication Publication Date Title
EA037366B1 (ru) Способ получения ингибитора parp, кристаллические формы и их применения
CN108314677B (zh) 一种ezh2抑制剂及其用途
WO2022017533A1 (zh) 用作cdk7激酶抑制剂的化合物及其应用
EA035680B1 (ru) Малеатные соли ингибитора braf киназы, кристаллические формы, способы их получения и применения
CN113454081A (zh) 咪唑并吡啶基化合物及其用于治疗增生性疾病的用途
JP2019526605A (ja) 置換２−ｈ−ピラゾール誘導体の結晶形、塩型及びその製造方法
BR112015017963A2 (pt) composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto
US20250222013A1 (en) Substituted pyridines as dnmt1 inhibitors
CN111825719A (zh) 一种含有芳胺基取代的吡咯并嘧啶类化合物、制备方法及其应用
HK40040143A (en) Process for preparing parp inhibitor, crystalline forms, and uses thereof
WO2019178801A1 (zh) 一类新型的苯氧基哌啶衍生物及其用途
TW202519531A (zh) 含丙烯酮類生物抑制劑的晶型及其製備方法和應用
HK40061853B (zh) 用作cdk7激酶抑制剂的化合物及其应用
CN117986267A (zh) 一种二噁烷并喹啉类化合物的盐、其晶型以及它们的制备方法及应用
HK40065851A (zh) 异柠檬酸脱氢酶(idh)抑制剂
HK40065851B (zh) 异柠檬酸脱氢酶(idh)抑制剂

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM